Methods and Compositions of Matter for Activating Class I Histone Deacetylases (HDACs) for Treatment of Human Disease
The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
Researchers
-
activators of class i histone deacetlyases (hdacs) and uses thereof
United States of America | Granted | 9,115,053 -
activators of class i histone deacetlyases (hdacs) and uses thereof
United States of America | Granted | 10,167,277 -
activators of class i histone deacetylases (hdacs) and uses thereof
United States of America | Granted | 11,084,803
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.